I Human platelet phenolsulphotransferase exists in two functional forms, M and P. In this study the substrate specificity of the two forms has been further delineated by correlating activities in different individuals with various substrates. m-Tyramine, noradrenaline, adrenaline, 5-hydroxytryptamine, p-hydroxyamphetamine, isoprenaline, salbutamol and l-naphthol were all specific substrates for the M form of the enzyme.
Introduction
Sulphate conjugation, catalyzed by phenolsulphotransferase (PST) (EC.2.8.2.1), is an important metabolic pathway, not only for phenolic monoamines and some of their metabolites but also for phenol and some phenolic drugs, including paracetamol and salicylamide (Williams, 1959) . Although there is a great deal of inter-individual variation in ability to form both the glucuronide and sulphate conjugates of these drugs, some individuals are relatively unable to form the sulphate conjugate of one or other (Caldwell et al., 1982 volunteers selected on the basis of their in vivo conjugation of these drugs.
Human platelet PST (Hart et al., 1979; Anderson & Weinshilboum, 1980; Rein etal., 1981) exists in two functional forms, PST P (specific for 30 Mm phenol) and PST M (specific for the monoamines, dopamine and tyramine) (Rein et al., 1982) . These two forms differ in substrate specificity, tissue distribution and inhibitor sensitivity, the P form being selectively inhibited by 10-z 2,6-dichloro4-nitrophenol (DCNP) (Rein et al., 1982) ; they appear to be under separate control (Bonham Carter et al., 1981) . To determine which forms of the enzyme metabolize paracetamol and salicylamide, we have examined the effect of DCNP on platelet PST activity using these drugs as substrates. We have confirmed our findings by correlating individual platelet PST activity values from the group of normal volunteers, using paracetamol and salicylamide as substrates, with those obtained using p-tyramine (for PST M) and phenol (for PST P) as substrates. There is a high degree of correlation between activities in different individuals with different substrates acting at the same active site (Bonham Carter et al., 1981) . We have also tested eight other phenolic compounds in this way in order to characterize the substrate specificities of PST M and P further.
The efficiency of the assay procedure was assessed for each of the different substrates used as there is evidence that it can vary considerably with different phenolic acceptors (Foldes & Meek, 1973; Baranczyk-Kuzmaetal., 1981) .
Methods

Materials
Materials for PST assay were essentially the same as previously described (Bonham Carter et al., 1981) 
Sample collection and platelet preparation
Venous blood samples (10 ml) were collected from 13 normal volunteers and platelets prepared on the same day, as previously described (Bonham Carter et al., 1981) ; the platelet pellet was washed with isotonic sucrose (1 ml/10 ml blood), resuspended in phosphate buffer (10 gM, pH 7.4; 1 ml/10 ml blood), divided into aliquots as required and stored deep frozen (-20°C). Care was taken not to allow plasma or platelet suspensions to heat up during centrifugation as PST M is thermolabile above 30°C (Bonham Carter et al., 1981) . The amount of glucuronide and sulphate conjugates of paracetamol or salicylamide excreted after administration of 1 g of either of these drugs had previously been estimated in 11 of the subjects for paracetamol and 9 of the subjects for salicylamide (Caldwell et al., 1982) .
PST assay
Platelet PST activities were measured by the same method as previously described (Bonham Carter et al., 1981) based on that of Foldes & Meek (1973) (200 ,ul, 0 .1 M). Foldes & Meek (1973) have demonstrated that this procedure removes at least 99.5% of unreacted PAPS in control experiments in the absence of enzyme and we have confirmed this. Any counts above a water blank level that remain in the supernatant after 2 precipitations in an assay are likely to be due to products of the PST enzyme reaction, i.e. sulphate esters. In order to assess the efficiency for different substrates, we carried out assays using the same batch of platelets and a range of phenolic acceptors with 6 tubes for each substrate. In each case, both supernatant and precipitate were counted, in duplicate for each substrate, after 1 precipitation, after 2 precipitations and after 3 precipitations. Blanks containing platelets, but water instead of acceptor substrate, were treated in the same way, and these counts were subtracted from those from the corresponding tubes containing acceptor substrate. In this way, the percentage radioactivity remaining in the third supernatant and that precipitated were calculated giving an indication of the solubility of the sulphate conjugates for each substrate.
Kn, determinations
Human platelet PST activity was measured using different concentrations of the substrates for which apparent Km values were not already known. The range of substrate concentrations used were as follows: for salicylamide 1-180 Am; for paracetamol 100-800 /LM, for m-tyramine, p-hydroxyamphetamine and isoprenaline 1 Am -1 mm. Apparent Km values were calculated by the direct linear plot method (Eisenthal & Cornish-Bowden, 1974) . Apparent Km values for most of the remaining sub-strates used have previously been reported (Rein et al., 1981; Bonham Carter et al., 1981; R. Sodha, personal communication) .
Inhibitor studies
The effect of the selective inhibitor, DCNP, on platelet PST activities using several acceptor substrates was examined using different concentrations of DCNP as described previously (Rein et al., 1982 (Rein et al., 1981) . In this study, by using a higher phenol concentration range a second, higher, apparent Km of 560 p.M was found.
Activity ofplatelet PST with differentsubstrates
The mean specific activity of platelet PST from the 13 subjects, using the range of acceptor substrates described, is given in (Caldwell et al., 1982) are shown in Table 2 . There is a substantial degree of interindividual variation in relative conjugating ability, with some evidence, in the case of paracetamol, that the effect derives from the inability of certain individuals to form sulphate conjugates (Caldwell et al., 1980 (Caldwell et al., , 1982 . These ratios were ranked and correlated with platelet PST activities in the same individuals using these 2 drugs, and p-tyramine and phenol, as substrates. Spearman rank correlation coefficients are shown in Table 3 . There was no significant positive correlation between paracetamol excretion data (11 individuals) and PST activities with paracetamol or p-tyramine (for PST M) as substrates. However, with phenol (for PST P) as substrate, there was a positive correlation which just reached statistical significance (P < 0.05, Table 3 ). There was no significant positive correlation between salicylamide excretion data (9 individuals) and PST activities with salicylamide, p-tyramine or phenol as substrates; in fact, all these correlation coefficients were negative, for reasons which are not immediately apparent.
.b 
Discussion
The results obtained in the recovery studies demonstrate that it is possible to use a wide range of neutral and basic phenols for this PST assay and obtain reasonably accurate specific activity values. Recovery values for the catecholamines, adrenaline and noradrenaline, were much poorer; the specific activities quoted have not been corrected and are therefore low. In their original paper, Foldes & Meek (1973) We have shown here that salicylamide is a PST P substrate at low concentration, becoming an M substrate at high concentration. Presumably the relatively low PST P activity is swamped at high concentration, because the PST M activity is so much greater. It is interesting that phenol itself becomes a substrate, again apparently exclusively for PST M at high concentration; this was confinned by using DCNP and also by the second much higher Km obtained for phenol sulphation. This finding may explain why Mulder & Scholtens (1977) found that (Caldwell et al., 1980 (Caldwell et al., , 1982 cannot be explained by a generalized deficiency of PST. Most sulphate conjugation of orally administered substances occurs in the gut and since there are similarities between gut and platelet enzymes (Anderson & Weinshilboum, 1980; Rein et al., 1981; Anderson et al., 1981) , the platelet seems to be a reasonable model to use for a study of this type where gut biopsies are not readily available. Whether the significant correlation between paracetamol sulphate excretion and PST P activity is a chance finding needs further investigation. Paracetamol is, to some extent, a substrate for PST P; however, at 850 /M and 8.5 mm it is predominantly a substrate for PST M and at the lower concentration of 90 ,UM there was no measurable PST activity at all.
There are other possible explanations for some individuals' relative inability to form sulphate conjugates of orally administered compounds, e.g. reduced drug availability at the conjugation site or modification of in vivo enzyme activity by the presence of endogenous inhibitors (Anderson & Weinshilboum, 1979) . These may also be the reasons why patients suffering from depressive illness who excrete significantly low levels of tyramine-Osulphate after oral tyramine administration (Sandler etal., 1975; Bonham Carter etal., 1978) , have normal platelet PST activity (Bonham Carter et al., 1981) . It is interesting, however, that poor sulphate conjugators of paracetamol are not necessarily poor sulphate conjugators of salicyclamide and vice versa (Caldwell et al., 1982) . Whether either of these groups are also poor sulphate conjugators of tyramine or another phenolic compound must be determined by future investigation.
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